News

Mon, 20/09/2021
Register now: 1st Symposium inflammation and imaging
When?: from November 2nd to November 4th 2021 Where?: Schloss (seat of the University Administration) Muenster Organizers: Co-operative Research Centres 1009, 1450, Transregio 128, and Clinical Research Unit 342 – together with Interdisciplinary Centre of Clinical Research (IZKF) and Excellence Cluster Cells in Motion (CiM) Registration is open now! More information: here...more
Mon, 09/08/2021
Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity
A close interaction between gut immune responses and distant organ-specific autoimmunity including the CNS in multiple sclerosis has been established in recent years. This so-called gut-CNS axis can be shaped by dietary factors, either directly or via indirect modulation of the gut microbiome and its metabolites. Here, SFB 128 PI Luisa Klotz and colleagues report […]...more
Thu, 28/01/2021
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” co-authored by SFB principal investigator Ari Waisman summarizes the findings on the disease-suppressing effects […]...more


Thu, 28/01/2021 | BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” co-authored by SFB principal investigator Ari Waisman summarizes the findings on the disease-suppressing effects of a non-inflammatory, nucleoside-modified mRNA vaccine in several clinically relevant mouse models of multiple sclerosis (MS). More . . .